entertainment -WSS

entertainment

author：knowledge 2025-10-01 15:29:38 - browse：82217

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Guidelines to prevent youth baseball injuries need more muscle

explore

WSS

George Santos makes 1st court appearance after pleading not guilty to 13 counts

State Dept. review finds Biden bears some blame for Afghanistan failures

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Illumina to lay off 10% of research and development team

After affirmative action ruling, medical educators look to 'holistic review'

DIEP, the 'gold standard' of breast reconstruction, is under threat

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

As demand for Covid shots wanes, Moderna seeks its next success

Novavax promises a turnaround & Lilly roils the obesity market

State Dept. review finds Biden bears some blame for Afghanistan failures

ADA: All diabetes patients should be screened for liver condition

In age of alternative facts, a scholarly course on calling out crap

Continuity nursing helped my family in our darkest PICU moments

After affirmative action ruling, medical educators look to 'holistic review'

Supreme Court strikes down Biden student loan forgiveness program

Medicare details structure of new drug price negotiation program

Walensky prepares to leave CDC — and Congress — behind

leisure time

Sports medicine is finally prioritizing gender equality

Affirmative action in medical school literally saved lives

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

The strange history of BMI, the body mass index

Drug repurposing or repositioning? The language matters

In age of alternative facts, a scholarly course on calling out crap

Wikipedia

explore

knowledge

focus